---
created: '2026-02-08T19:29:31.641205Z'
description: Potent first-generation typical antipsychotic (butyrophenone). Widely
  used for acute agitation, Tourette syndrome, and psychosis.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/drug/haloperidol/
slug: haloperidol
tags:
- drug
- antipsychotic
- agitation
- tourette_syndrome
- imported
- primekg
title: Haloperidol
type: drug
updated: '2026-02-08T19:29:31.641205Z'
---

# Haloperidol

## Overview
Haloperidol is a high-potency **typical antipsychotic** of the butyrophenone class. It is one of the most frequently used antipsychotics in emergency settings for **acute agitation** or psychosis due to its rapid onset (especially IM) and relatively clean cardiovascular profile (less hypotension than chlorpromazine).

However, its high affinity for D2 receptors in the striatum leads to a high incidence of **Extrapyramidal Symptoms (EPS)**, such as dystonia, akathisia, and parkinsonism.

## Indications
- **Schizophrenia**: Acute and maintenance treatment.
- **Acute Psychosis/Agitation**: Emergency management.
- **Tourette Syndrome**: Control of tics.
- **Delirium**: Often used in ICU settings (though evidence is debated).
- **Huntington's Disease**: Chorea management.

<!-- NEO4J_CONTENT_START -->
## Relationships
### Related
- ← [[Imipramine]] (drug)
```yaml
last_modified: '2026-01-26T06:47:59.154865'
source: obsidian
```
- ← [[Dopamine]] (neurotransmitter)
```yaml
last_modified: '2026-01-26T06:48:34.905107'
source: obsidian
```
- → [[Imipramine]] (drug)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[QT_Prolongation]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Dopamine_D2_Receptor]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Technetium_Tc-99m_pyrophosphate]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Methadyl_acetate]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Botulinum_Toxin_Type_B]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Extrapyramidal_Symptoms]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Methylprednisolone_hemisuccinate]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Tardive_Dyskinesia]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Chenodeoxycholic_acid]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[1-2-Phenylethyl-4-phenyl-4-acetoxypiperidine]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Sigma-1_Receptor]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Alpha-1_Adrenergic_Receptor]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Nalidixic_acid]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Tourette_Syndrome]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Estrone_sulfate]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Iofetamine_I-123]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[Gadobenic_acid]] (entity)
```yaml
last_modified: '2026-01-26T06:47:58.723650'
source: obsidian
```
- → [[QT_Prolongation]] (entity)
```yaml
last_modified: '2026-01-26T07:07:41.747424'
source: obsidian
```
- → [[Tourette_Syndrome]] (entity)
```yaml
last_modified: '2026-01-26T07:07:41.747424'
source: obsidian
```
- → [[Dopamine_D2_Receptor]] (entity)
```yaml
last_modified: '2026-01-26T07:07:41.747424'
source: obsidian
```
- → [[Tardive_Dyskinesia]] (entity)
```yaml
last_modified: '2026-01-26T07:07:41.747424'
source: obsidian
```
- → [[Delirium]] (entity)
```yaml
last_modified: '2026-01-26T07:07:41.747424'
source: obsidian
```
- → [[Extrapyramidal_Symptoms]] (entity)
```yaml
last_modified: '2026-01-26T07:07:41.747424'
source: obsidian
```
- → [[Agitation]] (entity)
```yaml
last_modified: '2026-01-26T07:07:41.747424'
source: obsidian
```
- → [[Sigma-1_Receptor]] (entity)
```yaml
last_modified: '2026-01-26T07:07:41.747424'
source: obsidian
```
- → [[Alpha-1_Adrenergic_Receptor]] (entity)
```yaml
last_modified: '2026-01-26T07:07:41.747424'
source: obsidian
```
- → [[Schizophrenia]] (entity)
```yaml
last_modified: '2026-01-26T07:07:41.747424'
source: obsidian
```
- → [[Dopamine]] (neurotransmitter)
```yaml
last_modified: '2026-01-26T07:07:41.747424'
source: obsidian
```

### Interactswith
- ← [[Methylprednisolone_hemisuccinate]] (entity)
```yaml
imported: '2025-12-26T11:56:38.309000+00:00'
source: PrimeKG
```
- ← [[Botulinum_Toxin_Type_B]] (entity)
```yaml
imported: '2025-12-26T11:56:38.319000+00:00'
source: PrimeKG
```
- ← [[Technetium_Tc-99m_pyrophosphate]] (entity)
```yaml
imported: '2025-12-26T11:56:38.331000+00:00'
source: PrimeKG
```
- ← [[Chenodeoxycholic_acid]] (entity)
```yaml
imported: '2025-12-26T11:56:38.360000+00:00'
source: PrimeKG
```
- ← [[Gadobenic_acid]] (entity)
```yaml
imported: '2025-12-26T11:56:38.379000+00:00'
source: PrimeKG
```
- ← [[Estrone_sulfate]] (entity)
```yaml
imported: '2025-12-26T11:56:38.403000+00:00'
source: PrimeKG
```
- ← [[Nalidixic_acid]] (entity)
```yaml
imported: '2025-12-26T11:56:38.487000+00:00'
source: PrimeKG
```
- ← [[Iofetamine_I-123]] (entity)
```yaml
imported: '2025-12-26T11:56:38.493000+00:00'
source: PrimeKG
```
- ← [[Methadyl_acetate]] (entity)
```yaml
imported: '2025-12-26T11:56:38.517000+00:00'
source: PrimeKG
```
- ← [[1-2-Phenylethyl-4-phenyl-4-acetoxypiperidine]] (entity)
```yaml
imported: '2025-12-26T11:56:38.528000+00:00'
source: PrimeKG
```
- → [[Imipramine]] (drug)
```yaml
imported: '2025-12-26T11:56:36.989000+00:00'
source: PrimeKG
```
<!-- NEO4J_CONTENT_END -->
## Relationships

### Modulates Neurotransmitter
- ⊣ [[Dopamine]] (neurotransmitter) - *Potent D2 antagonism*

### Modulates Protein
- ⊣ [[Dopamine D2 Receptor]] (protein) - *High Affinity Antagonist*
- ⊣ [[Alpha-1 Adrenergic Receptor]] (protein) - *Antagonist*
- ⊣ [[Sigma-1 Receptor]] (protein) - *Antagonist*

### Treats Condition
- → [[Schizophrenia]] (condition)
- → [[Agitation]] (condition)
- → [[Tourette Syndrome]] (condition)
- → [[Delirium]] (condition)

### Adverse Effects
- → [[Extrapyramidal Symptoms]] (condition) - *High risk*
- → [[Tardive Dyskinesia]] (condition)
- → [[QT Prolongation]] (condition)

## References
1. **Clinical Use**: Joy, C. B., et al. (2006). "Haloperidol versus placebo for schizophrenia." *Cochrane Database of Systematic Reviews*.
2. **Agitation**: Wilson, M. P., et al. (2012). "The psychopharmacology of agitation: consensus statement..." *Western Journal of Emergency Medicine*.